Sachiyo Minegishi
Plus aucun poste en cours
Profil
Sachiyo Minegishi worked as a Senior Director at Aegerion Pharmaceuticals, Inc. from 2012 to 2016, and as a Vice President at bluebird bio, Inc. from 2016 to 2020.
She also worked as the Head of Finance at Akouos, Inc. Ms. Minegishi completed her undergraduate degree at the Massachusetts Institute of Technology and earned an MBA from The Wharton School of the University of Pennsylvania.
Anciens postes connus de Sachiyo Minegishi
| Sociétés | Poste | Fin |
|---|---|---|
| BLUEBIRD BIO, INC. | Corporate Officer/Principal | 01/09/2020 |
| AEGERION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/04/2016 |
| AKOUOS | Director of Finance/CFO | - |
Formation de Sachiyo Minegishi
| Massachusetts Institute of Technology | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BLUEBIRD BIO, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Aegerion Pharmaceuticals, Inc.
 Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Akouos, Inc.
 Akouos, Inc. BiotechnologyHealth Technology Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The firm's lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA. | Health Technology |
